A clinical multicenter study on efficacy and safety of C1-inhibitor concentrate for clinical amniotic fluid embolism

A clinical multicenter study on efficacy and safety of C1-inhibitor concentrate for clinical amniotic fluid embolism - A clinical multicenter study on efficacy and safety of C1-inhibitor concentrate for clinical amniotic fluid embolism

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000015686

Enrollment

Registered

2014-11-13

Start date

2014-11-14

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Clinical amniotic fluid embolism

Interventions

None listed

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Patients with amniotic fluid embolism who fill the criteria as follows, 1) Symptoms should occur within 12 hours after delivery. 2) Massive postpartum hemorrhage with unknown etiology that occurred within 2 hours after delivery. 3) Disseminated intravascular coagulation (DIC).

Exclusion criteria

Exclusion criteria: Patients with anaphylactic reaction to C1-inhibitor concentrate.

Design outcomes

Primary

Measure	Time frame
Improvement of clinical symptom and laboratory data	—

Secondary

Measure	Time frame
Presence or absence of side effects	—

Countries

Japan

Contacts

Public ContactNaoaki Tamura

Hamamatsu University School of Medicine Obstetrics and Gynecology

ntamura@hama-med.ac.jp053-435-2309

Outcome results